NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar
CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications. To view the full press release, visit https://nnw.fm/MBIkc About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of…